• Tao Cheng, Bo-Fu Liu, Tian-Yong Han, Zhi-Han Gu, Pan Pan, and Yu Haifang.
• Department of Emergency Medicine.
• Medicine (Baltimore). 2021 Feb 26; 100 (8): e24863e24863.

BackgroundLiuhedan is a famous traditional Chinese medicine (TCM) formula used to treat acute pancreatitis (AP) in China. However, there is no systematic reviews for the evidence and the therapeutic effectiveness and safety of Liuhedan for treating AP. The aim of this study is to summarize previous evidence, assessing the efficacy and safety of Liuhedan in the treatment of AP.MethodsWe will search the EMBASE, WANFANG DATA, Web of Knowledge, CNKI, PubMed, ClinicalTrials.gov and Cochrane Library from inception to June 30, 2021 to retrieve relevant studies using the search strategy: ("Liuhedan" OR "Liuhe Pill" OR "Liu-He-Dan") AND ("pancreatitis" OR "pancreatitides"). Two authors independently judged study eligibility and extracted data. Heterogeneity will be examined by computing the Q statistic and I2 statistic.ResultsThis study assessed the efficiency and safety of Liuhedan for treating acute pancreatitis.ConclusionsThis study will provide reliable evidence-based evidence for the clinical application of Liuhedan for treating AP.Ethics And DisseminationEthical approval is unnecessary as this protocol is only for systematic review and does not involve privacy data. The findings of this study will be disseminated electronically through a peer-review publication or presented at a relevant conference.Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

18 keywords...

hide…